Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2021

View Archived Issues

CVL-231 safe in healthy volunteers; evaluation in schizophrenia patients ongoing

Studies reveal activity, mechanism of TAM kinase inhibitor PF-5807

Phase III study finds Xywav improves excessive daytime sleepiness

Observational study confirms good tolerability and efficacy of Intratect

Second pivotal study of IDP-126 achieves all coprimary endpoints with statistical significance

First patient dosed in investigator-initiated study of rigosertib in RDEB-associated SCC

Monopteros initiates phase I/Ib study of MPT-0118 in solid tumors

Phase III JUPITER-06 study of toripalimab plus chemotherapy meets primary endpoints

Medshine Discovery divulges PD-1/PD-L1 interaction inhibitors

Chinese investigators disclose HGFR and/or SRC and/or CSF1R inhibitors

Roche presents HBsAg secretion inhibitors

Alladapt initiates phase I/II Harmony Study of ADP-101

Shanghai Litedd identifies new ROR-gammaT agonists

Tolremo Therapeutics describes new DYRK1B inhibitors

Phase II trial of selective oral DHODH modulator vidofludimus in RRMS

FDA grants accelerated approval to Jemperli for dMMR endometrial cancer

ProtoKinetix resumes phase I trials of PKX-001-treated islet cells in patients with type 1 diabetes

ICAM-1 orchestrates radiotherapy abscopal effect

Discovery of JBI-1527, small molecule inhibitor of PD-L1/PD-1 interaction

OR-2805: a novel antibody targeting CD163 for the treatment of lung cancers

Zenith agrees with Astellas to study ZEN-3694 with enzalutamide in metastatic CRPC

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...